Huigg

Manufactured by MP Biomedicals

Sourced in United States

HuIgG is a purified human immunoglobulin G (IgG) product. IgG is the most abundant type of antibody in the human body and plays a crucial role in the immune system's response to pathogens and other foreign substances.

Automatically generated - may contain errors

Lab products found in correlation

Pd 10 desalting column, by GE Healthcare (1 mentions) Herceptin, by Gene Tech (1 mentions)

Close spelling variants of this product

Human immunoglobulin G (HuIgG) (6 citations)

2 protocols using huigg

Radiolabeling of Trastuzumab Immunoconjugate

Check if the same lab product or an alternative is used in the 5 most similar protocols

The bifunctional acyclic CHX-A″-DTPA chelating agent was conjugated to trastuzumab using established methods (10-fold molar excess of ligand to trastuzumab reaction ratio) as previously reported [4 (link),40 (link)]. The concentration of the protein of the immunoconjugate was determined (Lowry) and the average number of chelates per mAb assayed by a literature spectrophotometric method [41 (link),42 (link)]. Lutetium-177 (110 mCi) (PerkinElmer, Shelton, CT, USA), dissolved in 100 µL of 0.1 N HCl, was adjusted to pH 5.5 (5 M NH₄OAc buffer (pH 5.5)). The CHX-A″-trastuzumab immunoconjugate (2.0 mg) in 0.15 M NH₄OAc buffer (pH 6.5–7.0) was added to the buffered ¹⁷⁷Lu. After incubation (1 h, 37 °C), the radiolabeling reaction was halted with 0.1 M EDTA (4 µL, pH 6.0). Purification of the radioimmunoconjugate (RIC) was then affected by use of a PD-10 desalting column (GE Healthcare, Piscataway, NJ, USA). The non-specific control antibody for these experiments was prepared from HuIgG (MP Biomedicals, Santa Ana, CA, USA) using the identical conditions described for the specific agent.

Yong K.J., Milenic D.E., Baidoo K.E, & Brechbiel M.W. (2016). Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from 177Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. International Journal of Molecular Sciences, 17(5), 736.

+ Open protocol

+ Expand

Conjugation of Monoclonal Antibodies to Chelators

Check if the same lab product or an alternative is used in the 5 most similar protocols

Trastuzumab (Herceptin; Genetech, Inc., South San Francisco, CA) and panitumumab (Vectibix, Amgen, Thousand Oaks, CA) were purchased through the National Institutes of Health (NIH), Division of Veterinary Resources Pharmacy. Polyclonal human immunoglobulin (HuIgG; MP Biochemicals), purified from human serum, has no known antigen with which it reacts. HuM195, an anti-CD33 antibody, was kindly provided by Dr. McDevitt at the Memorial Sloan-Kettering Cancer Center.
Conjugation of monoclonal antibodies (mAb) with the bifunctional ligands, 1, 4, 7, 10-tetraazacyclododecane-N, N′,N″,N‴-tetraacetic acid (DOTA) or with trans-cyclohexyl-diethylenetriamine-pentaacetic acid (CHX-A″), was performed at a 10-fold molar excess of ligand to mAb according to established methods.^{26 (link)–32 (link)} The final protein concentrations were determined by the Lowry method using a BSA standard.^{33 (link)} The number of DOTA and CHX-A″ molecules bound to mAb were quantitated using spectrophotometric assays based on the titration of lead-Arsenazo(III) and yttrium- Arsenazo(III) complex, respectively. ^{34 (link), 35 (link)} The final chelate:protein ratios range from 2.6 to 4.0. HuIgG, or HuM195 similarly conjugated, served as negative controls in these studies.

Milenic D.E., Baidoo K.E., Kim Y.S., Barkley R, & Brechbiel M.W. (2017). Comparative Studies on the Therapeutic Benefit of Targeted α-Particle Radiation Therapy for the Treatment of Disseminated Intraperitoneal Disease. Dalton transactions (Cambridge, England : 2003), 46(42), 14591-14601.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!